Trial Profile
A Prospective, Randomized, Double-Blind, Parallel-Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects with Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2019
Price :
$35
*
At a glance
- Drugs Eprosartan (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Healthcare; Abbott Laboratories; AbbVie
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Feb 2013 Planned number of patients changed from 596 to 665 as reported by EudraCT.